Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome

Phase 4 Completed 400 enrolled Bristol-Myers Squibb Sanofi · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this clinical research study is to learn if irbesartan is superior to hydrochlorothiazide relative to effects on insulin sensitivity and glucose metabolism in hypertensive patients with metabolic syndrome.

Timeline

Start: 2005-11
Primary completion: 2007-02
Completion: 2007-02

Publications

Background Parhofer KG, Birkeland KI, DeFronzo R, Del Prato S, Bhaumik A, Ptaszynska A. Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND). Int J Clin Pract. 2010 Jan;64(2):160-8. doi: 10.1111/j.1742-1241.2009.02246.x. Epub 2009 Nov 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Hydrochlorothiazide	Unknown	25 mg	Oral
Subject	Irbesartan	Small molecule	300 mg	Oral

Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome

Summary

Timeline

Publications

Drugs

Indications